Peripheral/Endo

Surmodics Announces FDA Clearance of a New .018” Low-Profile PTA Balloon Dilation Catheter

EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its .018” Low-Profile percutaneous transluminal angioplasty (PTA) balloon dilation catheter, designed and indicated for a broad […]

Medtronic IN.PACT(TM) Admiral(TM) Drug Coated Balloon Receives FDA Approval to Treat Long SFA Lesions

DUBLIN – April 23, 2018 – Medtronic plc (NYSE: MDT) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the IN.PACT(TM) Admiral(TM) Drug-Coated Balloon (DCB) to treat long superficial femoral artery (SFA) lesions up to 360mm in patients with peripheral artery disease (PAD). Approval was based […]

Intact Vascular Announces $20 Million Series C Financing to Fund Company through PMA Approval of the Tack Endovascular System®

WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that it closed a Series C financing totaling $20 million. This financing is designed to fund the Company through Pre-Market Approval (“PMA”) of the Tack Endovascular System for the treatment of post-angioplasty […]

LimFlow Raises €27 Million ($33.5 Million) in Series C Financing Led by Sofinnova Partners to Advance Innovative Critical Limb Ischemia (CLI) Treatment

PARIS–(BUSINESS WIRE)–LimFlow SA, developer of innovative, peripheral endovascular technology transforming the treatment of critical limb ischemia (CLI), today announced it has secured €27 million ($33.5 million) in an oversubscribed Series C financing. The round was led by Sofinnova Partners, with continued participation from existing round B investors Bpifrance, the French […]

Global Interventional Cardiology and Peripheral Vascular Device Market 2018-2023 – A $26.3 Billion Market Opportunity

DUBLIN, April 10, 2018 /PRNewswire/ — The “Interventional Cardiology and Peripheral Vascular Device Market Report: Trends, Forecast and Competitive Analysis”report has been added to ResearchAndMarkets.com’s offering.  The global interventional cardiology and peripheral vascular device market is expected to reach an estimated $26.3 billion by 2023, and it is forecast to grow at a CAGR of 5.5% from […]

Angiograms and Angioplasty – Using your body’s vascular highway to identify and treat blockages

CHICAGO, April 9, 2018 /PRNewswire-USNewswire/ — Has your doctor prescribed an angiogram? If you are not sure what to expect, you’re not alone. The Society for Vascular Surgery angiogram information web page is the number one most-visited of all its patient information pages. What does a vascular surgeon do? In fact, says vascular […]

The global inferior vena cava (IVC) filters market is forecasted to grow at a CAGR of 11.24% during the period 2018-2022

NEW YORK, April 3, 2018 /PRNewswire/ — About Inferior Vena Cava (IVC) Filters The IVCF is a type of vascular filter that is inserted into the inferior vena cava to prevent blood clots from moving from the veins in the legs and pelvis to the lung, which can lead to life-threatening pulmonary embolism […]

IVC Filter Lawsuit News: C.R. Bard Ordered to Pay $3.6 Million at Conclusion of First Federal Bellwether Trial, Bernstein Liebhard LLP Reports

NEW YORK, April 2, 2018 /PRNewswire/ — C.R. Bard, Inc. has been ordered to pay $3.6 million to a Georgia woman who suffered serious complications after the company’s G2 inferior vena cava (IVC) filter fractured inside her body. The case was the first to go to trial in the U.S. District Court, District of Arizona, where more than […]

Symic Bio Announces 12-Month Results from the SHIELD Trial of SB-030 in Peripheral Vascular Disease

SAN FRANCISCO, April 2, 2018 /PRNewswire/ — Symic Bio, a biopharmaceutical company developing novel matrix-targeting biotherapeutics, today announced 12-month results from the Phase 1/2 SHIELD trial evaluating SB-030 in patients with peripheral vascular disease undergoing angioplasty. Under an extended trial protocol allowing assessment of secondary endpoint measurements at 12 months following intervention, patients […]